Introducing
a molecular engine that detects without amplifying the target
A programmable CRISPR-Cas detection complex that produces signal in seconds, with no target amplification step. Removing target amplification is what allows speed, breadth, and molecular accuracy to arrive together instead of trading against each other.
The VedaBio Platform
A fundamentally new molecular engine
Every amplification-based test inherits the constraints of copying the target: time, instrumentation, and limits on how many pathogens one reaction can carry. VedaBio is designed to detect the target directly and amplify only the signal, which changes what a point-of-care test can do.
Target amplification-free detection
Engineered CRISPR ribonucleoproteins and reporter molecules generate a robust signal directly from the target, with no copying step and no thermal cycler.
Swarming for sensitivity
Many carefully designed RNPs are aimed at a single target at once, multiplying the signal produced per copy. VedaBio's proprietary AI-guided RNP design raises Cas13a activity and lowers background, recovering the sensitivity that target amplification normally provides.
Pooling for coverage
Many pathogens are targeted in a single reaction sharing one reporter, acting as a biological OR: if any target in the pool is present, the well turns positive. Every target inside a pooled well is itself swarmed, so breadth and sensitivity come from one reaction.
The VedaBio Platform
How It Works
STEP 1:
Target Recognition and Signal Generation
Engineered ribonucleoproteins bind the nucleic-acid sequence of interest and immediately begin cleaving reporter molecules, releasing a fluorescent signal. Binding and signal generation happen as one continuous event, with no separate step in between. New targets can be added quickly, aided by computational and AI-based design.
Step 2:
Signal Amplification Without Target Amplification
Rather than copying the target, the system amplifies the signal through the sustained activity of the RNPs themselves. Each RNP continues cleaving reporters for as long as it stays bound, so signal builds continuously from the moment of binding. The result is molecular sensitivity in minutes, with no thermal cycler and no laboratory.
The VedaBio Platform
One platform. Built first for infectious disease.
The platform is broadly applicable, and VedaBio is deliberately focused. The first application is syndromic infectious-disease testing in decentralized care, where the gap between what the hospital can do and what urgent care can do is widest.
Infectious disease
Decentralized care
An expanding menu
Frequently Asked Questions
Common questions about the VedaBio platform and where it stands today.
How does it work?
A programmable CRISPR-Cas complex recognizes the pathogen's genetic sequence directly and releases a fluorescent signal that the instrument reads. Because no step copies the target, results arrive in minutes rather than hours.
Why does removing amplification matter?
Amplification is what makes molecular testing slow, instrument-heavy, and difficult to run outside a laboratory. Removing it is what makes it possible to design one test for speed, breadth, and molecular accuracy in a format simple enough for urgent care.
Does it require a laboratory?
No. The system is a benchtop instrument paired with a single-use cartridge, designed to run without laboratory infrastructure and without a trained laboratory operator.
Where is it designed to be used?
Decentralized care settings, beginning with urgent care, where patients arrive with acute symptoms and clinicians need an actionable answer during the visit.
Is it available today?
The system is in development and is not yet cleared by the FDA. Clinical data has been generated on a product-feature-ready cartridge and a prototype instrument, and VedaBio is working toward regulatory submission.
Interested in learning more?
Contact us to learn how the VedaBio Platform and our industry-leading discovery and development expertise open up new applications across infectious disease and beyond.